Glucagon-like peptide 1 receptor agonists approved in the United States
| Generic name | Administration route and frequency | Half-life | Gastric emptying delay |
|---|---|---|---|
| Dulaglutide | Subcutaneous injection weekly | 5 days | 120 minutes |
| Exenatide | Subcutaneous injection twice daily | 2–3 hours | 100–120 minutes |
| Exenatide, extended release | Subcutaneous injection weekly | 8–14 days | 144 minutes |
| Liraglutide | Subcutaneous injection daily | 11–15 hours | 70 minutes (median) |
| Semaglutide injection | Subcutaneous injection weekly | 1 week | 60 minutes |
| Semaglutide tablets | Oral daily | 1 week | Unknown |
Based on information from reference 2.